Posted inBiotechnology
Breaking the Blood–Brain Barrier in Pediatric CNS Tumors
The blood–brain barrier (BBB) has long stood as a formidable obstacle in the treatment of central nervous system (CNS) tumors,…
Posted inBiotechnology
Prenatal Exposure to Chlorpyrifos Linked to Brain Abnormalities in Children
A groundbreaking new study published in JAMA Neurology uncovers compelling evidence linking prenatal exposure to chlorpyrifos (CPF), a commonly used…
Posted inBiotechnology
Cadonilimab Shows Promise in Advanced Gynecological Cancers
In a groundbreaking retrospective study published recently in BMC Cancer, researchers have shed new light on the clinical potential of…
Posted inBiotechnology
Nerolidol and Cyclophosphamide Combat Breast Cancer Cells
In the relentless quest to conquer cancer, researchers continuously strive to unlock new avenues for effective treatment strategies. A recent…
Posted inBiotechnology
Hearing Aid Use Linked to Reduced Risk of Developing Dementia, Study Finds
A groundbreaking longitudinal study has revealed that the use of hearing aids among individuals with hearing loss can significantly reduce…
Posted inBiotechnology
VantAI plays matchmaker for Halda’s ‘hold-and-kill’ drugs in $1B deal
Halda Therapeutics has struck a deal with VantAI, entering into a pact that could be worth more than $1 billion…
Posted inBiotechnology
China’s RemeGen sells Asia rights to VEGF/FGF eye drug in $180M deal
China’s RemeGen has sold certain Asia rights to its phase 3-stage eye disease drug to Japan’s Santen Pharmaceutical for 250…
Posted inBiotechnology
Blood Biochemistry Reveals Post-Mortem Interval Insights
In the relentless pursuit of forensic precision, determining the post-mortem interval (PMI)—the elapsed time since death—has consistently represented a formidable…
Posted inBiotechnology
Spotting Supernovae at Lightning Speed: A New Era in Cosmic Discovery
Supernovae, the cosmic fireworks that occasionally light up the night sky, have long fascinated astronomers with their unpredictable and ephemeral…
Posted inBiotechnology
Opthea, still reeling from eye disease flops, ramps up cuts to 85% of staff and loses CEO
Opthea’s options may be shrinking as the eye disease biotech comes to terms with a pair of phase 3 failures,…